SCHEMBL6609666

SCHEMBL6609666

CNS(=O)(=O)c1ccc(-c2ccc(B(O)OC(C)(C)C(C)(C)O)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
KIF11 P52732 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 3/20 0.41
HTT P42858 1/20 0.41
NR3C2 P08235 1/20 0.39
GAA P10253 1/20 0.39
DRD1 P21728 1/20 0.39
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA3 P07451 2/20 0.38
CA4 P22748 2/20 0.38
CA6 P23280 2/20 0.38
CA5A P35218 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
CA13 Q8N1Q1 2/20 0.38
CA14 Q9ULX7 2/20 0.38
CA5B Q9Y2D0 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1365908 0.96 ALDH1A1 (0.46) ALDH1A1KIF11SMN1; SMN2LMNAHTT
SCHEMBL16734814 0.83 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2LMNACA12CA1
SCHEMBL17501064 0.80 ENPP2 (0.53) SMN1; SMN2GPR119PTGS2
SCHEMBL790008 0.79 CA2 (0.43) ALDH1A1HTTCA12CA1CA2
SCHEMBL6610483 0.77 HPGD (0.41) SMN1; SMN2HTTCA2HPGDMMP13
SCHEMBL15225532 0.76 MGLL (0.47) SMN1; SMN2LMNAHTTGAACA1
SCHEMBL6609673 0.76 ESR1 (0.38) KIF11LMNACA1CA2HPGD
SCHEMBL17394036 0.76 LMNA (0.44) ALDH1A1SMN1; SMN2LMNAHTTKDM4E
SCHEMBL6840781 0.75 SCN9A (0.47)
SCHEMBL6843044 0.74 MAPT (0.43) KIF11SMN1; SMN2LMNAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040266826-A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-30 US disclosed
EP-1423386-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-02 EP disclosed
WO-2003022842-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266826-A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors TNF, MMP9, MMP1 ALDH1A1 440/4885KIF11 3478/4885SMN1; SMN2 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.